Effects of a pharmacologically-induced shift of hemoglobin-oxygen dissociation on myocardial energetics during ischemia in patients with coronary artery disease

Journal of Cardiovascular Magnetic Resonance

Volumn 7, Issue 4, 2005, Pages 657-666

  Najjar, Samer S ^a,c   Bottomley, Paul A ^a   Schulman, Steven P ^a   Waldron, Michele M ^a   Steffen, Robert P ^b   Gerstenblith, Gary ^a   Weiss, Robert G ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Allos Therapeutics Inc   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Cardiac metabolism; Coronary artery disease; Hemoglobin oxygen dissociation; Magnetic resonance spectroscopy; Myocardial energetics; Myocardial ischemia

Indexed keywords

CREATINE PHOSPHATE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; ENERGY TRANSFER; EXERCISE; FEMALE; GRIP STRENGTH; HAND GRIP; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HIGH ENERGY PHOSPHATE; HUMAN; HYPOXEMIA; MALE; MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN AFFINITY; OXYGEN CONSUMPTION; OXYGEN DISSOCIATION CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREADMILL;

ADENOSINE TRIPHOSPHATE; AGED; ANALYSIS OF VARIANCE; ANILINE COMPOUNDS; ANTISICKLING AGENTS; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OXYGEN CONSUMPTION; OXYHEMOGLOBINS; PHOSPHOCREATINE; PHOSPHORUS ISOTOPES; PROPIONIC ACIDS; TREATMENT OUTCOME;

EID: 23844452320     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1081/JCMR-65610     Document Type: Article

References (33)

1. Shappell SD, Murray JA, Nasser MG, Wills RE, Torrance JD, Lenfant C. Acute change in hemoglobin affinity for oxygen during angina pectoris. N Engl J Med 1970; 1219-1224.
2. Kostuk WJ, Suwa K, Bernstein EF, Sobel BE. Altered hemoglobin oxygen affinity in patients with acute myocardial infarction. Am J Cardiol 1973; 295-299.
3. Sumimoto T, Takayama Y, Iwasaka T, Sugiura T, Takeuchi M, Tarumi N, Takashima H, Inada M. Oxygen delivery, oxygen consumption and hemoglobin-oxygen affinity in acute myocardial infarction. Am J Cardiol 1989; 975-979.
4. Lichtman MA, Cohen J, Young JA, Whitbeck AA, Murphy M. The relationships between arterial oxygen flow rate, oxygen binding by hemoglobin, and oxygen utilization after myocardial infarction. J Clin Invest 1974; 501-513.
5. Woodson RD, Torrance JD, Shappell SD, Lenfant C. The effect of cardiac disease on hemoglobin-oxygen binding. J Clin Invest 1970; 1349-1356.
6. Agostoni A, Lotto A, Stabilini R, Bernasconi C, Gerli G, Gattinoni L, Lapichino G, Sslvade P. Hemoglobin oxygen affinity in patients with low-output heart failure and cardiogenic shock after acute myocardial infarction. Eur J Cardiol 1975; 53-58.
7. Metcalfe J, Dhindsa DS, Edwards MJ, Mourdjinis A. Decreased affinity of blood for oxygen in patients with low-output heart failure. Circ Res 1969; 47-51.
8. Randad RS, Mahran MA, Mehanna AS, Abraham DJ. Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents. J Med Chem 1991; 752-757.
9. Abraham DJ, Wireko FC, Randad RS, Poyart C, Kister J, Bohn B, Liard JF, Kunert MP. Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry 1992; 9141-9149.
10. Kleinberg L, Grossman SA, Piantadosi S, Pearlman J, Engelhard H, Lesser G, Ruffer J, Gerber M. Phase 1 trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radio-enhancer, in newly diagnosed glioblastoma multiforme. J Clin Oncol 1999; 2593-2603.
11. Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, Roberts JD, Shaw EG, Pearlman AD, Venitz J, Dusenbery KE, Abraham DJ, Gerber MJ. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys 2001; 1133-1139.
12. Wahr JA, Gerber M, Venitz J, Baliga N. Allosteric modification of oxygen delivery by hemoglobin. Anesth Analg 2001; 615-620.
13. Nunnally RL, Bottomley PA. Assessment of pharmacological treatment of myocardial infarction by phosphorus-31 NMR with surface coils. Science 1981; 177-180.
14. Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med 1990; 1593-1600.
15. 31P magnetic resonance spectroscopy during handgrip exercise. Circulation 1994; 1709-1716.
16. DeBoer LW, Rude RE, Kloner RA, Ingwall JS, Maroko PR, Davis MA, Braunwald E. A flow- and time-dependent index of ischemic injury after experimental coronary occlusion and reperfusion. Proc Natl Acad Sci U S A 1983; 5784-5788.
17. Schaefer S, Camacho SA, Gober J, Obregon RG, DeGroot MA, Botvinick EH, Massie B, Weiner MW. Response of myocardial metabolites to graded regional ischemia: 31P NMR spectroscopy of porcine myocardium in vivo. Circ Res 1989; 968-976.
18. Robitaille PM, Lew B, Merkle H, Sublett E, Lindstrom P, From AH, Garwood M, Bache RJ, Ugurbil K. Transmural metabolite distribution in regional myocardial ischemia as studied with 31P NMR. Magn Reson Med 1989; 108-118.
19. Buchthal SD, den Hollander JA, Merz CN, Rogers WJ, Pepine CJ, Reichek N, Sharaf BL, Reis S, Kelsey SF, Pohost GM. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 2000; 829-835.
20. Weiss RG, Mejia MA, Kass DA, DiPaula AF, Becker LC, Gerstenblith G, Chacko VP. Preservation of canine myocardial high-energy phosphates during low-flow ischemia with modification of hemoglobin-oxygen affinity. J Clin Invest 1999; 739-746.
21. Bottomley PA, Hardy CJ, Roemer PB, Weiss RG. Problems and expediencies in human 31P spectroscopy. The definition of localized volumes, dealing with saturation and the technique-dependence of quantification. NMR Biomed 1989; 284-289.
22. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991; 795-801.
23. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, Mark DB, Marwick TH, McCallister BD, Thompson PD Jr, Winters WL, Yanowitz FG, Ritchie JL, Gibbons RJ, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Lewis RP, O'Rourke RA, Ryan TJ. ACC/AHA guidelines for exercise testing. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (committee on exercise testing). J Am CollCardiol 1997; 260-311.
24. Oski FA, Miller LD, Delivoria-Papadopoulos M, Manchester JH, Shelburn JC. Oxygen affinity in red cells: changes induced in vivo by propranolol. Science 1972; 1372-1373.
25. Gross GJ, Hardman HF. Alteration in oxyhemoglobin equilibrium (P-50) and myocardial oxygen consumption (MVO2) by nitroglycerin (GTN). J Pharmacol Exp Ther 1975; 346-355.
26. Schrumpf JD, Sheps DS, Wolfson S, Aronson AL, Cohen LS. Altered hemoglobin-oxygen affinity with long-term propranolol therapy in patients with coronary artery disease. Am J Cardiol 1977; 76-82.
27. Abraham DJ, Perutz MF, Phillips SE. Physiological and x-ray studies of potential antisickling agents. Proc Natl Acad Sci U S A 1983; 324-328.
28. Pagel PS, Hettrick DA, Montgomery MW, Kersten JR, Steffen RP, Warltier DC. RSR13, a synthetic modifier of hemoglobin-oxygen affinity, enhances the recovery of stunned myocardium in anesthetized dogs. J Pharmacol Exp Ther 1998; 1-8.
29. Kilgore KS, Shwartz CF, Gallagher MA, Steffen RP, Mosca RS, Boiling SF. RSR13, a synthetic allosteric modifier of hemoglobin, improves myocardial recovery following hypothermie cardiopulmonary bypass. Circulation 1999; 11351-11356.
30. Gambier C, Wierinckx M, Clerbaux T, Detry B, Liardet MP, Marville V, Frans A, Gustin P. Haemoglobin oxygen affinity and regulating factors of the blood oxygen transport in canine and feline blood. Res Vet Sci 2004; 83-88.
31. Clerbaux T, Gustin P, Detry B, Cao ML, Frans A. Comparative study of the oxyhaemoglobin dissociation curve of four mammals: man, dog, horse and cattle. Comp Biochem Physiol, Comp Physiol 1993; 687-694.
32. Kleinberg L, Grossman SA, Carson K, Lesser G, O'Neill A, Pearlman J, Phillips P, Herman T, Gerber M. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase 11 new approaches to brain tumor therapy CNS consortium safety and efficacy study. J Clin Oncol 2002; 3149-3155.
33. Johnson BD, Shaw LJ, Buchthal SD, Bairey Merz CN, Kim HW, Scott KN, Doyle M, Oison MB, Pepine CJ, den Hollander J, Sharaf B, Rogers WJ, Mankad S, Forder JR, Kelsey SF, Pohost GM, National Institutes of Health-National Heart, Lung, and Blood Institute. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 2993-2999.